Compass Pathways' Q2 loss widens on commercial readiness activity costs
CMPS•Outlook
- COMPASS Pathways expects to complete final NDA submission for COMP360 in Q4 2026
- Company anticipates commercial launch of COMP360 in the first half of 2027, pending approvals
- Current cash position expected to fund operations into 2028
Overview
- UK mental health biotech's Q2 operating income missed analyst estimates
- Net loss widened yr/yr, mainly due to non-cash warrant fair value adjustments
- Company ended Q2 with $433 mln cash, expected to fund operations into 2028
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | $1.88 | ||
| Q2 Net Loss | $253.79 mln | ||
| Q2 Operating Income | Miss | -$52.37 mln | -$47.06 mln (13 Analysts) |
| Q2 Operating Expenses | $52.37 mln | ||
| Q2 Pretax Loss | $253.46 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Compass Pathways PLC is $20.00, about 69.5% above its August 4 closing price of $11.80.
